Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2024

Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review

Résumé

Background: new-onset atrial fibrillation remains a common complication in critical care settings, often necessitating treatment when the correction of triggers is insufficient to restore hemodynamics. The treatment strategy includes electric cardioversion in cases of hemodynamic instability and either rhythm control or rate control in the absence of instability. Landiolol, an ultrashort beta-blocker, effectively controls heart rate with the potential to regulate rhythm. Objectives This review aims to compare the efficacy of landiolol in controlling heart rate and converting to sinus rhythm in the critical care setting. Methods: We conducted a comprehensive review of the published literature from 2000 to 2022 describing the use of landiolol to treat atrial fibrillation in critical care settings, excluding both cardiac surgery and medical cardiac care settings. The primary outcome assessed was sinus conversion following landiolol treatment. Results: Our analysis identified 17 publications detailing the use of landiolol for the treatment of 324 critical care patients. While the quality of the data was generally low, primarily comprising non-comparative studies, landiolol consistently demonstrated similar efficacy in controlling heart rate and facilitating conversion to sinus rhythm in both non-surgical (75.7%) and surgical (70.1%) settings. The incidence of hypotension associated with landiolol use was 13%. Conclusions: The use of landiolol in critical care patients with new-onset atrial fibrillation exhibited comparable efficacy and tolerance in both non-surgical and surgical settings. Despite these promising results, further validation through randomized controlled trials is necessary.
Fichier principal
Vignette du fichier
jcm-13-02951.pdf (837.94 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04595066 , version 1 (05-06-2024)

Identifiants

Citer

Bruno Levy, Michel Slama, Ines Lakbar, Julien Maizel, Hiromi Kato, et al.. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. Journal of Clinical Medicine, 2024, 13 (10), pp.2951. ⟨10.3390/jcm13102951⟩. ⟨hal-04595066⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More